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1 Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effects of a 2 romifidine infusion in standing horses34 Abstract5 Objective To evaluate the effect of a romifidine infusion on antinociception and sedation, and 6 to investigate its relationship to plasma concentration.7 Study design Prospective, experimental, non-randomized trial.8 Animals Ten healthy adult warmblood horses.9 Methods Romifidine (loading dose: 0.08 mg kg-1, infusion: 0.03 mg kg-1 hour-1) was 10 administered intravenously (IV) over 120 minutes. Romifidine plasma concentrations were 11 determined by capillary electrophoresis. Sedation quality and nociceptive thresholds were 12 evaluated at regular time points before, during and after romifidine administration. The 13 nociceptive RIII reflex was elicited by electrical stimulation at the thoracic limb using a 14 dedicated threshold tracking algorithm and recorded by electromyography at the deltoid 15 muscle. A pharmacokinetic-pharmacodynamic model was established and correlation between 16 romifidine plasma concentration and main output variables tested.17 Results A two compartmental model best described the romifidine pharmacokinetic profile. 18 The nociceptive thresholds increased compared to baseline in all horses from 10 to 146 19 minutes after romifidine administration (p < 0.05). Peak effect reached 5.7 ± 2.3 times the 20 baseline threshold. The effect/concentration relationship followed a counter-clockwise 21 hysteresis loop. The mean plasma concentration was weakly correlated to nociceptive 22 thresholds (p < 0.01,  = 0.392). The sedative effects were significant until 160 minutes but 23 variable, not correlated to plasma concentration (p = 0.067), and weakly correlated to 24 nociceptive thresholds (p < 0.01,  = 0.33).
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25 Conclusions and clinical relevance Romifidine elicited a marked antinociceptive effect. 26 Romifidine-induced antinociception appeared with a delayed onset and lasted longer than 27 sedation after discontinuing its administration. 28 Keywords antinociception, electrical stimulation, horses, nociceptive withdrawal reflex, 29 pharmacokinetics, romifidine.3031 Introduction32 Among sedative and analgesic drugs currently available, alpha-2 adrenergic agonists are 33 essential for equine standing interventions. Compared to xylazine and detomidine, romifidine 34 is more selective for the alpha-2 adrenergic receptor, evokes longer lasting sedation and tends 35 to produce less ataxia at an equipotent sedative dose (England et al. 1992; Hamm et al. 1995; 36 Nannarone et al. 2007). These characteristics may be advantageous for sedation during long 37 lasting standing procedures, even though differences between alpha-2 adrenergic agonists 38 may diminish when titrated to effect as a continuous infusion over longer time (Ringer et al. 39 2013).40 The objective of this study was to characterize the antinociceptive effect of romifidine 41 infusion in standing horses. Previous studies have already investigated it under experimental 42 conditions. The hoof withdrawal latency in response to thermal stimulation (Figueiredo et al. 43 2005; Christovão et al. 2006) was significantly prolonged after an intravenous (IV) bolus of 44 romifidine. The duration of effect appeared to be dose-dependent. The withdrawal latency in 45 response to electrical stimulation increased four-fold, 15 minutes after an IV romifidine bolus 46 (Moens et al. 2003), but less notably in response to mechanical stimulation. The nociceptive 47 withdrawal reflex (NWR) threshold, assessed by electromyography, also significantly 48 increased in response to single and repeated electrical stimulations after an IV romifidine 49 bolus (Spadavecchia et al. 2005; Rohrbach et al. 2009). However, these studies only 50 investigated specific time points after romifidine administration without correlation to plasma 
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51 concentrations, preventing a precise description of the time course (onset, duration) of 52 antinociception elicited by romifidine, as well as comparison to its sedative properties. This 53 limitation may explain the various durations of effect reported by the former studies, as well 54 as the different results regarding the relationship between sedation and antinociception. 55 Previous authors reported sedation outwearing analgesia (Lizarraga & Janovyak 2013; El-56 Kammar & Gad 2014), the opposite (Rohrbach et al. 2009; Costa et al. 2015), or similar time 57 courses (Lizarraga et al. 2017). 58 A novel automated reflex threshold tracking system, based on a validated algorithm (von 59 Dincklage et al. 2009), provides an opportunity to assess, nearly continuously, the NWR 60 threshold. This methodology might allow for a more precise characterization of the time 61 course of the antinociceptive activity, and realization of pharmacokinetic-pharmacodynamic 62 (PKPD) modelling. The present study aimed at evaluating the antinociceptive effects of a 63 romifidine infusion, using the automated assessment of the NWR threshold, and to investigate 64 its relationship to plasma concentrations by creating a PKPD model. The main hypothesis was 65 that romifidine infusion increases the NWR threshold in relation to its plasma concentration.6667 Material and methods68 Sample size calculation69 A baseline NWR threshold of 4.0 ± 0.5 mA can be expected in the horse (Spadavecchia et al. 70 2002; Spadavecchia et al. 2003; Spadavecchia et al. 2005; Rohrbach et al. 2009), and a two-71 fold increase with a standard deviation of 50% after romifidine administration would be 72 considered relevant. Using a two-tailed paired t-test and targeting an alpha of 0.05 and a 73 power of 95%, a sample size of 6 horses would be required (G*Power v.3.1.9.2, **, **). 74 A baseline sedation score of 2 (0-3) can be expected, and an increase to 5 (3-7) after 75 romifidine administration would be arbitrarily considered relevant. Using a Wilcoxon signed 76 rank test and targeting an alpha of 0.05 and a power of 95%, a sample size of 8 horses would 
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77 be required (G*Power v.3.1.9.2, **, **).78 For a correlation (H1:  > 0.85, H0:  < 0.05) between plasma concentrations and the main 79 output variables, targeting an alpha of 0.05 and a power of 95%, a sample size of 10 horses 80 would be required (G*Power v.3.1.9.2, **, **).81 Therefore, we chose to include 10 horses in this study. A total of nine geldings and one mare 82 were recruited. Median age was 5 (4-16) years and mean weight was 551 ± 44 kg.83 Study design84 This prospective experimental study was carried as a non-randomized provocation trial to 85 evaluate the effect of romifidine over time on the nociceptive threshold and sedation quality 86 compared to baseline. It was approved by the Committee for Animal Experiments of **, ** 87 (Permission number: ** **).88 Animals89 Ten clinically healthy warmblood horses were recruited from the National Equine Military 90 centre. Informed consent was obtained from the centre; the horses were owned by the 91 government. Healthy horses free from any pharmacological treatment in the two months prior 92 to the trial were eligible for inclusion.93 All horses were kept in single boxes under regular housing conditions. The experimental box 94 was a normal stall at the same facilities. A horse not participating in the study was placed in 95 the adjacent box. The timing of the procedures was standardized and constant environmental 96 conditions were maintained throughout the experimental phase. Food was withheld for 12 97 hours prior to drug administration. In case of major complications, including cardiovascular 98 collapse, severe ataxia with recumbency attempts and intolerance to the electrical stimulation, 99 the horse would receive appropriate treatment and be excluded from the study.100 Animal preparation
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101 On the morning of the experiment the animal was weighed, walked into the experimental box 102 and left undisturbed for at least 10 minutes. Physical examination was performed prior to 103 instrumentation.104 Both jugular veins were catheterized (13 gauge 105 mm catheter, Intranule; Vygon, **, **) 105 after subcutaneous infiltration of 2 mL of Lidocaine 2% (Lidocain 2% Streuli; Streuli Pharma, 106 **, **) The catheter on the right side was connected to a bag of Ringer’s lactated solution that 107 contained a port, in the extension set, for romifidine constant rate infusion (CRI); the left 108 catheter was used for blood sampling. 109 Stimulation and recording surface electrodes were applied to the skin for NWR measurement. 110 Skin preparation, placement site, and electrode-skin impedance were standardized. Two self-111 adhesive surface electrodes (Bluesensor N; Ambu, **) placed 0.5 cm apart over the left 112 deltoid muscle, and a ground electrode (Bluesensor VL; Ambu, **) placed over the greater 113 tubercule of the humerus were used for electromyographic (EMG) recordings (Fig. S1). In 114 addition, two self-adhesive surface electrodes (Bluesensor N; Ambu, **) were placed 0.5 cm 115 apart over the lateral digital nerve, between the coronary band and the metacarpophalangeal 116 joint for electrical stimulation (Fig. S1). For each electrode, the skin was clipped, cleaned and 117 prepared with abrader tape (Red dot Trace Prep; 3M, **), and the electrode-skin impedance 118 was checked and kept below 2 kOhm for the duration of the experiment. If necessary, the 119 electrode was replaced. Once instrumented, the horse was left undisturbed for 10 minutes 120 before starting baseline measurements, and then loosely tied to the wall for the duration of the 121 experiment. 122 Drug administration123 After determination of the baseline NWR threshold (at least 10 minutes of a stable NWR 124 threshold and not less than 20 minutes after starting stimulation), romifidine 0.08 mg kg-1 IV 125 (Sedivet 10 mg mL-1; Boehringer Ingelheim, **, **) was administered by hand over 1 minute. 126 Immediately thereafter, the romifidine infusion (diluted to 1 mg mL-1 with NaCl solution) was 
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127 started at 0.03 mg kg-1 hour-1 and maintained over 120 minutes using a calibrated syringe 128 pump (Perfusor Space Syringe Pump; B. Braun, **).129 NWR threshold determination 130 Electrical stimulations and EMG recordings were performed through a dedicated unit 131 (Dolosys Pain Tracker; Dolosys **, **). The NWR threshold was automatically determined 132 using a bracketing design according to the validated continual RIII reflex threshold tracking 133 algorithm (von Dincklage et al. 2009). Each stimulation consisted of five individual 134 rectangular pulses of a duration of 1 ms delivered at 200 Hz. The EMG activity was recorded 135 for 500 ms with a sampling frequency of 1 kHz, starting 100 ms before the stimulation onset 136 (noise range). The time window of interest for detecting the NWR was set between 60 ms and 137 200 ms after stimulation onset (NWR range). Occurrence of the NWR was defined as an 138 interval peak Z score above 10, meaning that the difference between the maximum EMG 139 amplitude in the NWR range and the mean EMG amplitude in the noise range had to be above 140 the ten-fold of the standard deviation of the EMG amplitudes in the noise range (Rhudy & 141 France 2007). Intensity of the first stimulus was set at 1 mA with a step change of 0.3 mA, 142 increasing to 0.5 mA after three stimuli with a minimum step size of 0.3 mA. The step size 143 increased to 0.5 mA when three changes of the stimulation intensity occurred in the same 144 direction, and decreased back to 0.3 mA after three direction changes. The interstimulus 145 interval was set to 10 seconds with 30% interval randomization. The measurements were 146 automatically discarded when the EMG amplitude exceeded 15 μV in the noise range (0-100 147 ms before stimulation), and the stimulation intensity was repeated. Estimation of the NWR 148 threshold is performed following every valid stimulation (not discarded due to inappropriate 149 noise) by a logistic regression of the last 12 stimuli (von Dincklage et al. 2009).150 Romifidine plasma concentrations151 For determining romifidine plasma concentrations, venous blood samples were taken 10 152 minutes before, and 3, 5, 7, 15, 30, 55, 75, 90, 120, 150, 180 and 210 minutes after starting 
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153 romifidine infusion. For each sample, 10 mL blood was removed from the left jugular catheter 154 and discarded, then 10 mL blood was collected into heparinized tubes and kept on ice until 155 processing. The plasma was separated by centrifugation (10 minutes at 2000 x g, 10 °C), and 156 stored in plastic cryotubes at -20 °C until analysis. Plasma concentrations were determined by 157 capillary electrophoresis. The method used was a modification of assays previously described 158 for the enantioselective determination of ketamine and its metabolites (Theurillat et al. 2016) 159 and methadone and its main metabolite (Theurillat et al. 2019) in plasma. Briefly, the 160 developed assay involves liquid/liquid extraction of romifidine and the added internal 161 standard D-(+)-norephedrine from 100 µL of plasma using dichloromethane at alkaline pH 162 and electrokinetic injection of the analytes (8 kV for 15 s) from the reconstituted extract 163 across a 50 mM phosphate buffer (pH 3.0) plug. A Proteome Lab PA 800 enhanced 164 instrument (Beckman Coulter, Fullerton, CA, USA) equipped with a 50 µm I.D. fused-silica 165 capillary (Polymicro Technologies, Phoenix, AZ, USA) of 45 cm total length (effective length 166 35 cm) was used. The running buffer comprised 100 mM phosphate buffer (pH 3.0) to which 167 0.14 % highly sulfated γ-cyclodextrin (Beckman Coulter) was added. A voltage of 20 kV was 168 applied and the current was about 48 µA. Sample storage and capillary cartridge temperatures 169 were set to 18 and 16 °C, respectively. Analyte detection was achieved at 210 nm (PDA 170 detector). Quantification of romifidine concentrations was based on five-level internal 171 calibration using corrected peak areas. The calibration range for romifidine was 10 – 200 172 ng/mL and the quantification limit was 5 ng/mL. For romifidine levels of 20 and 80 ng/mL, 173 interday precision (n=6) was 5.22 % and 2.36 %, respectively. Accuracy assessments revealed 174 romifidine concentrations that varied less than 3 % from the target values.175 PKPD modelling176 For determining the romifidine pharmacokinetic profile, plasma concentrations were 177 modelled with a commercially available software (Phoenix 64 v.8.0.0.3176 2017, 178 WinNonLin/NLME application; Certara Inc, **, **). The most suitable mammillary 
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179 compartmental model for romifidine was determined for each individual, separately. 180 Assessment was based on the appearance of the observed and predicted concentrations, data 181 fit, diagnostic plots, Akaike information criterion (AIC) and residual analysis. Non-182 compartmental analysis was also performed to orient initial estimates. Various models were 183 evaluated using different Non-Linear Mixed Effects algorithms. The most represented model 184 (algorithm and number of compartments) was then applied to all the horses. Similarly, a 185 population model was obtained considering all the collected samples.186 A PKPD modelling was then performed to correlate plasma concentrations to the 187 antinociceptive effect of romifidine. The individual NWR threshold in non-medicated horses 188 (mean over the 5 minutes before romifidine administration) was used as baseline for each 189 horse and the relative nociceptive threshold (divided by the individual baseline) was 190 calculated. The effect of romifidine plasma concentrations on both the absolute and the 191 relative nociceptive thresholds were modelled as an indirect response model:192 dR/dt = Kin – Kout x R 193 Where dR/dt is the rate of change of the response R (the intensity threshold required to elicit a 194 NWR in response to the electrical stimulation) over time, Kin is the first-order rate constant 195 for the factors promoting intrinsic tolerance to the noxious stimulation (increasing Kin will 196 increase the threshold) and Kout is the zero-order rate constant for the factors increasing the 197 nociceptive sensibility (increasing Kout will decrease the threshold). The fitted baseline 198 response, R0, is the ratio Kin / Kout. Several models were evaluated based on data fit, residual 199 analysis and diagnostic parameters. Romifidine was found to modulate nociceptive sensibility 200 (increase Kout) in a non-linear fashion (following a sigmoid Imax model) according to the 201 following PKPD equation:202 dR/dt = Kin – { (Kin / R0) x [1- ( (ImaxROM x CROMn)/(IC50 ROM+CROMn) x R ) ] }203 Where Imax is proportional to the maximal threshold (no unit), IC50 is the drug concentration 204 (ng mL-1) that would achieve 50% of the maximum threshold increase, and n is the slope of 
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205 the concentration-effect relationship (no unit).206 The addition of an effect compartment on romifidine plasma concentration to model time 207 delay with the observed effect was tested.208 dCe/dt = ke0 x (CROM-Ce)209 Where ke0 is the first order rate constant for the effect compartment, and Ce replaces CROM in 210 the former PKPD equation.211 Other pharmacodynamic parameters212 The degree of sedation was scored by a multifactorial sedation scale (MFSS) ranging from 0 213 (no sedation) to 10 (heavily sedated) and was based on attitude, standing ability, head 214 position, eye aperture and ear movement (Rohrbach et al. 2009). A total score of at least 5 215 was considered to represent effective sedation. Relative head height above the ground 216 (HHAG) was also measured (Ringer et al. 2012). Sedation was assessed at selected time 217 points (baseline, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 125, 130, 135, 140, 145, 218 150, 160, 170, 180, 190, 200 and 210 minutes).219 Heart rate, respiratory rate and gut motility were evaluated at regular intervals after sedation 220 assessment. Adverse effects were registered throughout the experiment as well as frequency 221 of urination, defecation and behavioural reactions.222 Statistical analysis223 Statistical analyses were carried out using SigmaPlot for Windows (SigmaPlot v.14; Systat 224 Software GmbH, **, **). Data were tested for normal distribution by visual inspection and 225 confirmed by a Shapiro-Wilk test. Normally distributed data are presented as mean ± SD for 226 values from a sample, or mean [95% confidence interval] for values from a population. Non-227 normally distributed data are presented as median (range). The effect of treatment on NWR 228 thresholds and HHAG was tested using one-way ANOVA for repeated measures. The effect 229 of treatment on sedation scores was tested using Friedman ANOVA on ranks for repeated 230 measures. Post-hoc pairwise multiple comparisons were performed with a Tukey test. Linear 
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231 correlation between plasma concentrations, NWR thresholds, and sedation scores were tested 232 with Pearson product moment analysis.233234 Results235 All horses completed the study. 236 Pharmacokinetic profile237 A mean steady plasma concentration for romifidine of 28.3 [24.4-32.2] ng mL-1 was 238 maintained from 30 to 120 minutes after start of the infusion (Fig. 1). A two compartmental 239 model best described romifidine pharmacokinetic profile (Table S1). 240 Antinociceptive effect and PKPD modelling241 The mean baseline NWR threshold before romifidine administration was 4.6 ± 1.7 mA (Table 242 1). The NWR threshold increased (p < 0.001) compared to baseline in all horses from 10 to 243 146 minutes after romifidine administration (p < 0.05), up to a peak value of 5.7 ± 2.3 times 244 the baseline. The onset for the antinociceptive effect of romifidine, arbitrarily defined as the 245 time to reach 75% of the maximal effect for each horse, was 22.2 ± 6.9 minutes and the offset 246 of the antinociceptive effect, arbitrarily defined as the time to decrease to 25% of the maximal 247 effect for each horse once the infusion was stopped, as 36.7 ± 14.6 minutes. When 248 romifidine reached steady plasma concentrations (30 to 120 minutes after infusion start), the 249 NWR threshold was 4.3 [3.1-5.5] times above the baseline (Fig. 2). One horse (identified 250 number 4) appeared as an outlier increasing its NWR threshold 9.5 ± 0.7 times above its 251 baseline. Among the other horses, the NWR threshold during this time period was 3.8 [3.2-252 4.4] times above the baseline.253 The relative NWR threshold appeared to represent better romifidine antinociception than the 254 absolute threshold which exhibited more individual variability and a larger confidence 255 interval. It was more significantly correlated to romifidine plasma concentrations and the 256 PKPD models were more accurate (Fig. 3). Therefore, results for PKPD modelling are 
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257 presented only for the relative threshold. An indirect sigmoid Emax response model was 258 obtained for each horse as well as for the population, with ke0, Kin, EC50 and n as PD 259 parameters including random effect (Emax = 1, Kout = 0.9-1.1*Kin). The best population 260 estimates were 0.46 minute-1, 0.27 minute-1, 10.9 ng mL-1, and 1.07, respectively (Table S2).261 The graphical representation of the relative NWR threshold over the plasma concentration 262 (from the population PKPD model) followed a counter-clockwise hysteresis loop (Fig. S2). 263 The individual relative NWR thresholds were not well correlated (p = 0.19,  = 0.19) to their 264 respective romifidine plasma concentrations (Fig. 4). This was supported by individual 265 variability of IC50 (9.66 ± 3.49 ng mL-1). Still, a weak linear correlation (Pearson Product 266 Moment,  = 0.392) was significant (p = 0.007) when the horse identified as number 4 267 (outlying high NWR threshold) was excluded from analysis.268 Other pharmacodynamic effects269 The median sedation score reached its maximal value of 7 (5-9) at the first evaluation (5 270 minutes after infusion start). The individual sedation scores reached their maximal value of 8 271 (6-9) at 20 (5-70) minutes after infusion start. All the horses reached effective sedation 272 (MFSS  5) within 20 minutes after the start of the infusion. The sedation score was 6 (2-9) 273 during steady plasma concentrations of romifidine (from 30 to 120 minutes after infusion 274 start). The sedation scores were different from baseline (p < 0.05) up to 160 minutes after the 275 infusion start. The sedation offset (score < 5) occurred before the end of the infusion in 5 276 horses (identified as numbers 2, 4, 5, 8, 9) and 5 (0-25) minutes after termination of the 277 infusion in the five other horses. The sedation scores obtained during romifidine infusion 278 were not correlated with plasma concentrations (Pearson Product Moment,  = 0.26, p = 279 0.067). However, sedation scores exhibited a weak linear correlation with their respective 280 mean NWR thresholds (Pearson Product Moment,  = 0.33, p < 0.001). During steady plasma 281 concentrations of romifidine (from 30 to 120 minutes after infusion start) the relative HHAG 282 was 50 [45-55] % exhibiting large variability and appeared to not adequately reflect sedation 
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283 quality, thus results are not reported.284 No major adverse effects were observed during the study. All horses tolerated the nociceptive 285 stimulations well, without exaggerated behavioural reactions. The romifidine caused 286 increased urination in all the horses. One horse (identified as number 10) exhibited severe 287 ataxia without attempts to be recumbent.288289 Discussion290 In the present study, administration of an intravenous romifidine infusion in standing horses 291 led to a significant increase in the NWR threshold (about 4 times its baseline), supporting an 292 antinociceptive effect of romifidine. The relevant antinociceptive effect lasted from 293 approximately 20 minutes after the start of the infusion until approximately 35 minutes after 294 the end of infusion. The amplitude of the NWR threshold increase was weakly correlated to 295 individual romifidine plasma concentration. Sedation quality and duration did not correlate 296 with the antinociceptive effects. At the dose regimen administered, the sedation became 297 insufficient (MFSS <5) before the end of romifidine infusion in half of the horses.298 The nociceptive threshold measured in the present study was in agreement with former 299 studies. Baseline values measured before treatment administration were in accordance with 300 previous reports applying electrical stimulation at the thoracic limb in conscious, non-301 medicated horses (Spadavecchia et al. 2002; Spadavecchia et al. 2003; Spadavecchia et al. 302 2005; Rohrbach et al. 2009). Romifidine increased the nociceptive threshold to 5.8 times its 303 baseline after a single bolus of 0.08 mg kg-1 (Rohrbach et al. 2009). Another publication 304 reported a milder effect of romifidine on the nociceptive threshold (an increase to only 3 times 305 its baseline), however a different method of determination as well as different time points (at 306 5 and 25 minutes after administration) were used (Spadavecchia et al. 2005). In the present 307 study, the romifidine infusion (0.03 mg kg-1 hour-1) maintained a nearly constant nociceptive 308 threshold.
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309 As in previous reports, the nociceptive threshold increased already a few minutes after 310 romifidine administration (Spadavecchia et al. 2005; Rohrbach et al. 2009). However, past 311 reports were limited to measurements at few time points with large intervals. The 312 methodology used here characterizes continuously the effect of the drug allowing for a precise 313 determination of threshold changes. In the present study, the nociceptive threshold reached a 314 significant difference from baseline values 10 minutes after administration. The onset of 315 maximal antinociception (defined as reaching 75% of the peak nociceptive threshold) was 316 about 20 minutes after the start of romifidine administration. After termination of the infusion, 317 in the present study, the threshold decreased down to 25% of the peak value within 35 318 minutes and was not significantly different from baseline anymore already at 26 minutes. This 319 is markedly different than the 55 or 120 minutes reported in previous publications after IV 320 bolus (Spadavecchia et al. 2005; Rohrbach et al. 2009). This difference may be the result of 321 methodological diversity including different administration regimen as well as individual 322 variability for termination of the effect.323 Although the nociceptive threshold increased and decreased rapidly after starting and 324 terminating the romifidine infusion, the relationship between the observed effect and the 325 concentration time course in blood obtained from the PKPD model revealed a marked 326 hysteresis. Counter-clockwise hysteresis, together with the prolonged termination of the 327 effect, support a time delay due to a possible longer equilibration time between plasma and 328 the site of action or a mechanistic response delay (Fan & de Lannoy 2014). A similar delay 329 has been previously observed for the sedative effects of alpha-2 agonists, and is reported to be 330 more pronounced with romifidine than xylazine or detomidine (Wojtasiak-Wypart et al. 2012, 331 Ringer et al. 2013). 332 The sedative effect of romifidine administered as a single IV bolus (0.08-0.1 mg kg-1) has 333 been reported to correlate to the drug plasma concentration (Wojtasiak-Wypart et al. 2012; de 334 Vries et al. 2016; Cenani et al. 2017; Romagnoli et al. 2017). In the present study, sedation 
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335 appeared within 5 minutes after romifidine administration and vanished very rapidly after 336 discontinuation. This is less than the 60 minutes of recovery reported in a previous study 337 (Ringer et al. 2012), even though different assessment endpoints were applied. Moreover, half 338 of the horses did not maintain satisfactory sedation during romifidine infusion, while the same 339 dosage had been proven satisfactory in other studies (Ringer et al. 2012; Ringer et al. 2013). 340 Interestingly, similar romifidine plasma concentrations close to 30 ng mL-1 were observed 341 (Ringer et al. 2012). The setting, and in particular whether the horses were stimulated, 342 manipulated or received painful interventions, will very probably influence the relationship 343 between quality of sedation and antinociceptive intensity. The plasma concentrations were 344 similar, but nociceptive stimulation was not elicited in the latter investigations. When 345 applying the same dose regimen in horses undergoing dental procedures, 5 out of 11 required 346 additional romifidine boli (Marly et al. 2014).347 Beside the sedation being more variable and more difficult to quantify, its time course 348 differed markedly from antinociception. There are controversial results on this point in the 349 literature (Valverde 2010), probably in part due to difficulty to evaluate depth of sedation. 350 Data obtained in the present study suggests that sedation both appears and stops earlier than 351 antinociceptive effects. This is in agreement with some of the previous publications 352 (Rohrbach et al. 2009; Costa et al. 2015).353 Applying different evaluation systems to quantify depth of sedation probably contributes to 354 these discrepancies, and difficulties to provide a reliable index of sedation have been reported 355 (Schauvliege et al. 2019). Many of the former studies reported HHAG to be an adequate 356 method to quantify sedation in horses (England et al. 1992; Hamm et al. 1995; Freeman & 357 England 2000; Figueiredo et al. 2005; Ringer et al. 2012; Ringer et al. 2013). In the present 358 study, the results obtained using HHAG appeared largely variable and poorly correlated to 359 sedation. This was probably the result of our experimental setting, where horses were tied up, 360 continuously stimulated, subject to clinical examinations and blood was regularly sampled. 
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361 Other limitations of the current study should be taken into consideration. It is not clear in 362 which extent the NWR threshold accurately reflects a clinical level of pain perceived by the 363 horses, and the threshold value cannot be directly transposed to a clinical situation. However, 364 NWR threshold has been associated with pain threshold in humans (Willer 1977), and is used 365 extensively as a non-invasive and objective method to study nociception and its 366 pharmacological modulation (Willer & Bathien 1977). The methodology has also been 367 validated for assessment of nociception in horses (Spadavecchia et al. 2002; Luna et al. 2015; 368 Spadavecchia et al. 2016). For instance, the amplitude of the EMG-derived NWR at low 369 stimulation intensity (at threshold level) has been correlated with an active behavioural 370 reaction (limb withdrawal) in response to painful stimulations (Spadavecchia et al. 2002; 371 Spadavecchia et al. 2003).372 This study has been performed in healthy, experimental animals; therefore caution should be 373 taken while extrapolating the results to horses under clinical conditions. Moreover, sex 374 distribution was uneven. Sex differences in pain and antinociception have been reported in 375 humans and animal models (Greenspan et al. 2007) therefore, these results should be 376 extrapolated carefully to the general equine population. Another potential limitation is the 377 lack of a control group. In a non-randomized provocation trial, the effect of treatment cannot 378 be distinguished from the effect of time. Depending on the stimulation paradigm used, 379 habituation or sensitization to the nociceptive stimulation may happen (Arendt-Nielsen et al. 380 2000; von Dincklage et al. 2013). Previous validation trials of the experimental setting applied 381 in the present study showed that the NWR is expected to remain constant over time (von 382 Dincklage et al. 2009). Finally, the observer was aware of the treatment. Observer bias has 383 been reported when using subjective measurement scales (Hrobjartsson et al. 2013). This may 384 apply for the evaluation of sedation, but determination of the NWR threshold was performed 385 automatically by the pain tracker unit and was not expected to be influenced by the observer.386 In conclusion, the present study confirms the marked antinociceptive effect of romifidine. 
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387 Furthermore, the study provides a precise characterization of its time course when 388 administered as an infusion regimen. Compared to sedation, romifidine antinociception 389 appeared with a delayed onset and lasted longer after discontinuing its administration. 
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Table 1 Absolute values of the nociceptive withdrawal reflex threshold (NWRT) 
measured during intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-
1 hour-1 for 120 minutes) in ten experimental horses. The baseline values (±SD) were 
measured before treatment. The peak values were the maximal NWRT (±SD) measured 
during romifidine administration. The mean values were the average NWRT [95% 
confidence interval] measured between 30 and 120 minutes after start of the infusion.
Parameters Horse identification number
1 2 3 4 5 6 7 8 9 10 Mean SD/CI
Baseline (mA) 2.4 4.0 3.4 6.1 2.8 5.9 5.9 3.3 4.7 7.5   4.6 1.7
Peak value (mA) 15.7 18.3 19.6 69.1 16.2 36.5 19.5 10.9 26.8 37.3 27.0 17.2
Mean value (mA) 10.4 14.1 14.9 58.1 13.0 25.7 15.6 8.7 17.9 29.5 20.8 11.8-29.8
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Table S1 Individual and population (Pp) pharmacokinetic parameters for romifidine 
administered as an intravenous infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 
for 120 minutes) in ten experimental horses.
1 2 3 4 5 6 7 8 9 10 Pp
V1 (mL kg-1) 349.42 774.80 702.48 171.46 663.96 577.89 1006.58 146.74 495.43 856.16 250.32
V2 (mL kg-1) 886.8 1709.6 892.8 1306.3 1221.3 1848.6 3264.1 1495.8 1031.9 1469.1 842.6
k10 (minute-1) 0.07 0.04 0.03 0.11 0.03 0.04 0.02 0.09 0.05 0.01 0.10
k12 (minute-1) 0.10 0.04 0.07 0.21 0.03 0.05 0.03 0.19 0.09 0.03 0.22
k21 (minute-1) 0.04 0.02 0.06 0.03 0.02 0.01 0.01 0.02 0.04 0.02 0.07
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Table S2 Individual and population (Pp) pharmacokinetic-pharmacodynamic parameters 
for the effect of romifidine administered as an intravenous infusion (0.08 mg kg-1 
followed by 0.03 mg kg-1 hour-1 for 120 minutes) on the relative nociceptive withdrawal 
reflex threshold in ten experimental horses.
1 2 3 4 5 6 7 8 9 10 Pp
Kin (minute-1) 0.59 0.17 0.29 0.26 0.25 0.20 0.25 0.24 0.27 0.24 0.27
Kout (minute-1) 0.58 0.19 0.29 0.28 0.27 0.20 0.25 0.24 0.29 0.26 0.25
ke0 (minute-1) 0.11 0.95 0.60 0.51 1.00 0.50 0.66 0.51 0.97 1.00 0.46
IC50 (ng mL-1) 9.27 12.87 6.90 7.84 7.52 10.00 6.02 13.77 6.29 16.12 10.93
n 0.99 2.06 0.90 1.00 0.97 1.00 0.96 1.35 0.87 1.62 1.07
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Individual plasma concentrations of romifidine (ng mL-1) (red dots) and predicted concentration from the 
population pharmacokinetic model (straight line) during and after intravenous romifidine infusion (0.08 mg 
kg-1 followed by 0.03 mg kg-1 hour-1 for 120 minutes) in ten experimental horses. 
151x117mm (300 x 300 DPI) 
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Mean (±SD) nociceptive withdrawal reflex threshold relative to individual baseline values during and after 
intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 for 120 minutes) in ten 
experimental horses. 
149x117mm (300 x 300 DPI) 
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Individual relative nociceptive withdrawal reflex (NWR) thresholds (thin crosses) during and after 
intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 for 120 minutes) in ten 
experimental horses, as well as the predicted time-course of the NWR threshold (PK/PD model) for the 
population (straight line) and two out of the ten horses (green and red dashed lines). 
149x117mm (300 x 300 DPI) 
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Individual means (±SD) of the relative nociceptive withdrawal reflex thresholds against their corresponding 
mean (±SD) plasma concentration during intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 
mg kg-1 hour-1 for 120 minutes) in ten experimental horses. Data are calculated from time points 30, 55, 
75, 90, and 120 minutes after the start of the romifidine infusion. 
149x117mm (300 x 300 DPI) 
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Placement of recording (a) and stimulating (b) electrodes for measurement of the nociceptive withdrawal 
reflex prior to and during a continuous intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg 
kg-1 hour-1 for 120 minutes). 
1349x772mm (72 x 72 DPI) 
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Counter-clockwise hysteresis loop of the relationship between effect (nociceptive withdrawal reflex threshold 
increase) and plasma concentration during intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 
mg kg-1 hour-1 for 120 minutes) based on a population pharmacokinetic-pharmacodynamic model from ten 
experimental horses. 
148x118mm (300 x 300 DPI) 
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Figure legends
Figure 1 Individual plasma concentrations of romifidine (ng mL-1) (red dots) and 
predicted concentration from the population pharmacokinetic model (straight line) 
during and after intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 
hour-1 for 120 minutes) in ten experimental horses.
Figure 2 Mean (±SD) nociceptive withdrawal reflex threshold relative to individual 
baseline values during and after intravenous romifidine infusion (0.08 mg kg-1 followed 
by 0.03 mg kg-1 hour-1 for 120 minutes) in ten experimental horses.
Figure 3 Individual relative nociceptive withdrawal reflex (NWR) thresholds (thin 
crosses) during and after intravenous romifidine infusion (0.08 mg kg-1 followed by 
0.03 mg kg-1 hour-1 for 120 minutes) in ten experimental horses, as well as the predicted 
time-course of the NWR threshold (PK/PD model) for the population (straight line) and 
two out of the ten horses (green and red dashed lines).
Figure 4 Individual means (±SD) of the relative nociceptive withdrawal reflex 
thresholds against their corresponding mean (±SD) plasma concentration during 
intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 for 120 
minutes) in ten experimental horses. Data are calculated from time points 30, 55, 75, 90, 
and 120 minutes after the start of the romifidine infusion.
Figure S1 Placement of recording (a) and stimulating (b) electrodes for measurement of 
the nociceptive withdrawal reflex prior to and during a continuous intravenous 
romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 for 120 minutes). 
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Figure S2 Counter-clockwise hysteresis loop of the relationship between effect 
(nociceptive withdrawal reflex threshold increase) and plasma concentration during 
intravenous romifidine infusion (0.08 mg kg-1 followed by 0.03 mg kg-1 hour-1 for 120 
minutes) based on a population pharmacokinetic-pharmacodynamic model from ten 
experimental horses.
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